LONDON and NEW YORK - MeiraGTx Holdings plc (NASDAQ:MGTX), a clinical-stage genetic medicines company, has announced encouraging results from its latest clinical trial, MGT-GAD-025, focused on treating Parkinson’s disease. The study met its primary goal of safety and tolerability, while also showing significant improvements in key efficacy endpoints for patients with idiopathic Parkinson's disease.
The trial, which lasted 26 weeks, was a randomized, double-blind, sham-controlled study that compared the effects of two dosage levels of AAV-GAD, a gene therapy product, with a sham procedure. The participants, all of whom had a history of responsiveness to levodopa treatment, received the therapy through bilateral infusion into the subthalamic nucleus.
The high dose group, comprising five subjects, demonstrated an 18-point average improvement in the Unified Parkinson’s Disease Rating Scale (UPDRS) Part 3 off medication score, which is considered a clinically meaningful change. Both high and low dose groups showed significant enhancements in the Parkinson’s Disease Questionnaire (PDQ-39) scores, a measure of quality of life, with improvements of 8 and 6 points from baseline, respectively.
Dr. Ali Rezai, the principal investigator of the AAV-GAD study, expressed optimism about the outcomes, highlighting the substantial motor score improvements and quality of life enhancements in patients receiving the high dose treatment. Alexandria Forbes, Ph.D., president and CEO of MeiraGTx, echoed this sentiment, noting the safety of AAV-GAD at all doses and the potential for the therapy to normalize circuit function in Parkinson’s disease.
The promising results from this small, sham-controlled study have paved the way for further clinical development. The company plans to engage with regulators in the US, Europe, and Japan with the aim of initiating a Phase 3 study.
Parkinson’s disease affects nearly a million people in the U.S. and over 10 million worldwide. While most patients initially respond to dopamine replacement therapy, its effectiveness can wane over time, making alternative treatments like AAV-GAD a significant focus for researchers.
MeiraGTx specializes in genetic medicines and has developed a proprietary manufacturing platform for its products. The company’s pipeline includes late-stage clinical programs and end-to-end manufacturing capabilities.
This news article is based on a press release statement from MeiraGTx Holdings plc.
In other recent news, MeiraGTx Holdings has been the subject of various financial analyses and developments. Piper Sandler maintained its Overweight rating on MeiraGTx shares, highlighting potential near-term catalysts and an anticipated milestone payment of $285 million from a partnership with Johnson & Johnson. This payment is linked to the first commercial sale of AAV-RPGR, a gene therapy product, next year.
RBC Capital adjusted its price target for MeiraGTx to $9.00, while maintaining an Outperform rating. This followed the company's second-quarter results and a $50 million equity financing deal, led by a $30 million investment from Sanofi (NASDAQ:SNY). The company is also in discussion with the FDA about its treatment for xerostomia and expects pivotal trial results for its treatment of X-linked retinitis pigmentosa later this year.
MeiraGTx has also announced a public offering of 12.5 million ordinary shares at $4 each, expecting to generate $50 million in gross proceeds. The proceeds are intended for general corporate purposes, including research and development expenses and clinical trial costs.
Simultaneously, Chardan Capital Markets initiated coverage on MeiraGTx with a Buy rating, expressing confidence in the company's gene therapy pipeline. The firm highlighted the promising Phase 1 data from the AQUAx study, recent agreements with Janssen Pharmaceuticals, and the strength of MeiraGTx's preclinical pipeline.
These are recent developments that indicate the ongoing financial and research activities of MeiraGTx.
InvestingPro Insights
As MeiraGTx Holdings plc (NASDAQ:MGTX) advances its promising Parkinson's disease treatment, investors should consider some key financial metrics and expert insights. According to InvestingPro data, the company's market capitalization stands at $359.13 million, reflecting its position as a clinical-stage biotech firm with significant potential.
InvestingPro Tips highlight that MGTX has seen a significant return over the last week, with a 1-week price total return of 11.81%. This recent uptick could be attributed to the positive clinical trial results announced for its Parkinson's disease therapy. However, it's important to note that the company is currently not profitable over the last twelve months, which is not uncommon for clinical-stage biotech companies investing heavily in research and development.
Another InvestingPro Tip indicates that MGTX is quickly burning through cash, a factor that investors should monitor closely given the capital-intensive nature of clinical trials and drug development. On a positive note, the company operates with a moderate level of debt and its liquid assets exceed short-term obligations, providing some financial flexibility as it progresses towards potential commercialization of its therapies.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights that could be valuable in assessing MGTX's investment potential. There are 5 more InvestingPro Tips available for MGTX, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.